کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2750541 1149344 2014 12 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Adverse Event Management of mTOR Inhibitors During Treatment of Hormone Receptor–Positive Advanced Breast Cancer: Considerations for Oncologists
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی بیهوشی و پزشکی درد
پیش نمایش صفحه اول مقاله
Adverse Event Management of mTOR Inhibitors During Treatment of Hormone Receptor–Positive Advanced Breast Cancer: Considerations for Oncologists
چکیده انگلیسی

Breast cancer (BC) is diagnosed in nearly 1 in 3 women with cancer in the United States; one third of these patients have regional lymph node metastases at the time of diagnosis. The 5-year survival rate of patients with metastatic BC is very low, and approximately 40,000 women were expected to die of the disease in 2013. About 75% of patients with BC have hormone receptor–positive (HR+) disease, which is often managed with endocrine therapy; however, most patients eventually have resistance to these therapies. Recently, the mammalian target of rapamycin (mTOR) inhibitor everolimus, in combination with exemestane, improved progression-free survival (PFS) of patients with advanced BC, leading to its approval by the US Food and Drug Administration. Because adverse events (AEs) associated with everolimus might differ from AEs that oncologists who treat patients with BC are more familiar with, everolimus AEs and their effective management are reviewed in this article. Possible dose adjustments of everolimus for patients with renal or hepatic impairment and strategies for minimizing potential interactions of everolimus with other drugs and food are also discussed.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Clinical Breast Cancer - Volume 14, Issue 5, October 2014, Pages 297–308
نویسندگان
,